![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737220300608-gr2.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
![The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram](https://www.researchgate.net/publication/343802292/figure/fig1/AS:954140192681984@1604496157129/The-effect-of-tepotinib-on-c-MET-b-catenin-ERK-and-c-MYC-protein-levels-in-GC-cells.png)
The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram
![Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44 Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44](https://www.mdpi.com/cancers/cancers-14-03444/article_deploy/html/images/cancers-14-03444-g002.png)
Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
![Cancers | Free Full-Text | Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC Cancers | Free Full-Text | Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC](https://www.mdpi.com/cancers/cancers-14-02150/article_deploy/html/images/cancers-14-02150-g001.png)
Cancers | Free Full-Text | Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
![Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer](https://www.frontiersin.org/files/MyHome%20Article%20Library/632256/632256_Thumb_400.jpg)
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
A study to learn about the effects and safety of tepotinib plus osimertinib in patients with MET-amplified non-small cell lung c
![Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management - ScienceDirect Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730422000389-ga1.jpg)
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management - ScienceDirect
![Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial - Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -](https://www.thelancet.com/cms/attachment/702e279d-3221-4646-87a7-81747f6ef558/gr1_lrg.gif)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
![JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review](https://pub.mdpi-res.com/jpm/jpm-11-01370/article_deploy/html/images/jpm-11-01370-g001.png?1639567299)
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
![Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | British Journal of Cancer Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01380-3/MediaObjects/41416_2021_1380_Fig1_HTML.png)
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | British Journal of Cancer
![SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004220310294-fx1.jpg)
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect
![Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial - Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -](https://www.thelancet.com/cms/attachment/c3fa4d47-311c-4fed-85fe-d11407aa2d05/gr3.jpg)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
![Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation | Journal of Hematology & Oncology | Full Text Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-022-01299-z/MediaObjects/13045_2022_1299_Fig1_HTML.png)
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation | Journal of Hematology & Oncology | Full Text
![PDF] The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. | Semantic Scholar PDF] The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e3a026eea26e4f2336369569f57302b519c3abf6/3-Figure1-1.png)